Coastar Therapeutics

Coastar Therapeutics is developing a novel biological payload delivery platform to overcome key challenges in genetic medicine, specifically immune clearance and lack of targeting. The company's core technology leverages engineered red blood cell membranes to create a stealthy, targeted delivery vehicle for a range of genetic payloads. Coastar is actively engaging with global partners and has gained recognition as an innovative startup, evidenced by its selection as a 2025 'Cool Company' and participation in major industry conferences like BIOCOM 2026.

An Erythrocyte Derived Membrane (EDM) based gene delivery platform designed to protect genetic medicines (DNA, RNA, viral vectors) from immune clearance and enable precision targeting for scalable in vivo delivery.

Coastar competes with established lipid nanoparticle companies (e.g., Moderna, BioNTech) and other bio-inspired delivery startups (e.g., exosome-focused firms). Its differentiation hinges on proving its erythrocyte-derived membrane platform offers superior immune evasion, targeting, and safety compared to existing non-viral delivery systems.